Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Saturday, November 28, 2020 · 531,669,512 Articles · 3+ Million Readers

The Global Oligonucleotide Therapy Market Will Be Driven By Increasing Number Of Cancer Cases And Grow At 12.2% CAGR

Oligonucleotide Therapy Market Report 2020-30: Covid 19 Growth And Change

Oligonucleotide Therapy Market Global Report 2020-30: Covid 19 Growth And Change

The Business Research Company’s Global Oligonucleotide Therapy Market Report 2020-30: Covid 19 Growth And Change

LONDON, GREATER LONDON, UK, September 29, 2020 / -- The rise in the number of cancer cases across the globe is likely to contribute to the oligonucleotide therapy market growth during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oligonucleotide therapy market over the forthcoming years.

The global oligonucleotide therapy market size is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The global oligonucleotide therapy market size is then expected to recover and reach $1.25 billion in 2023 at a CAGR of 12.2%.

During the historic period, the oligonucleotide therapy market share was restrained by the low number of drug approvals by the Food and Drug Administration (FDA). As of January 2020, the market only had 11 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market

Developers and providers in the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, the FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects.

The oligonucleotide therapy market share consists of sales of oligonucleotide therapy related services by entities (organizations, sole traders and partnerships) that manufacture oligonucleotide therapy products. Oligonucleotide therapy uses synthetic oligonucleotides, which can be artificially produced in labs, to inactivate disease-causing genes.

Here Is A List Of Similar Reports By The Business Research Company:
Gene Editing Global Market Report 2020-30: Covid 19 Growth And Change

Gene Therapy Market Global Report 2020-30: Covid 19 Growth And Change

Nucleic Acid Based Gene Therapy Market Global Report 2020

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release